J&J, Orbimed to bid jointly in biotech incubator tender

Johnson & Johnson has made only a few investments in Israel in recent years, but its teaming up with Orbimed in the tender may indicate a change.

Johnson & Johnson (NYSE: JNJ) and OrbiMed Advisors LLC will jointly bid in the Office of the Chief Scientist's biotech incubator tender. Johnson & Johnson, which has early-stage operations in Israel, will bid in the tender through Johnson & Johnson Development Corporation (JJDC).

JJDC has made only a few investments in Israel in recent years, but its teaming up with Orbimed in the tender may indicate a change. JJDC VP venture investments Zeev Zehavi handles investments in Israel and Europe. Johnson & Johnson is very active in Israel; subsidiaries include Biosense Webster Inc., acquired in the mid-1990s and which now has over $1 billion in annual sales; and Omrix, acquired in 2009. The two companies have hundreds of employees in Israel.

Orbimed Israel, which manages $222 million, is a major investor in Israeli life sciences companies. It has invested $30 million to date, including $7.12 million in RDD Pharma, $4.3 million in Otic Pharma Ltd., $8 million each in Medigus Ltd. (TASE:MDGS) and BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX), and $3 million in cCam Biotherapeurics Ltd.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) invested $20 million in Orbimed Israel's first financing round in 2010. Although Teva has stopped making independent investments in early-stage ventures, except in its core businesses of neurology and the central nervous system, and cancelled its plans to establish a corporate venture capital fund, it has kept its contractual commitment to Orbimed. Teva's management may consider this as a logical financial investment that will not detract from management's attention.

Published by Globes [online], Israel business news - www.globes-online.com - on February 19, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס